Gilead Sciences Inc. said Tuesday it will join with other drugmakers to manufacture and sell its Covid-19 treatment remdesivir outside of the U.S., farming out production of the medicine to ensure supply meets global demand.
Gilead said it is in discussions with pharmaceutical- and chemical-manufacturing companies to license the rights to make the drug remdesivir for Europe, Asia and in the developing world through at least 2022.
…
